For Everyone
-
ACIP Meeting Information
- ACIP Meeting Agendas
- ACIP Meeting Minutes
- Presentation Slides: October 23-24, 2024 Meeting
- June 26-28, 2024 Meeting
- February 28-29, 2024 Meeting
- October 25-26, 2023 Meeting
- September 22, 2023 Meeting
- September 12, 2023 Meeting
- August 3, 2023 Meeting
- June 21-23, 2023 Meeting
- April 19, 2023 Meeting
- February 22-24, 2023 Meeting
- February 28-29, 2024
- October 25-26, 2023
- September 22, 2023
-
GRADE Evidence Tables – Recommendations in MMWR
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2023-2024 Formulation)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Persons Aged 12-17 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6–11 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine for Children Aged 6 Months–5 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Novavax COVID-19 Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Children 5-11 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Persons Aged 12-15 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Children Aged 6 Months–4 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine
- GRADE Analysis: Dengvaxia® Dengue Vaccine
- GRADE: rVSVΔG-ZEBOV-GP Ebola vaccine for persons in the U.S. population who are at potential occupational risk of exposure to Ebola virus (species Zaire ebolavirus)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY)
- GRADE Hepatitis A vaccine for post-exposure prophylaxis in adults >40 years of age
- ACIP Grading for Yellow Fever Vaccine Booster Doses
- ACIP Grading for Hepatitis A vaccine for persons experiencing homelessness
- ACIP GRADE for use of Hepatitis A Vaccine for Persons With HIV
- ACIP Grading of Recommendations Assessment, Development and Evaluation (GRADE) for Hepatitis B (HepB) Vaccine in Adults
- ACIP Grading Hep B Vaccine Recs for Adults with Diabetes
- ACIP Grading for HEPLISAV-B Vaccine
- ACIP Grading: Recombinant Zoster Vaccine and Herpes Zoster Live-Attenuated Vaccine
- ACIP Grading 2-dose schedule for HPV vaccination
- ACIP Grading 9vHPV in Females and Males
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years
- ACIP Grading of Recommendations Assessment, Development and Evaluation (GRADE) for Booster Dose of Rabies Vaccine
- ACIP GRADE for use of HPV vaccine in adults ages 27-45 years
- ACIP Grading Recommendations for HPV Vaccine for Males
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Safety of Influenza Vaccines for Persons with Egg Allergy
- GRADE: Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged ≥65 Years
- ACIP Grading for Japanese Encephalitis Vaccine in Children
- ACIP Evidence to Recommendations for Japanese Encephalitis Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS® (orthopoxvirus) vaccine booster (Policy Questions 3 and 4)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS® (orthopoxvirus) vaccine heterologous for those who received ACAM2000 primary series
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use of JYNNEOS (orthopoxvirus) vaccine primary series for research, clinical laboratory, response team, and healthcare personnel (Policy Questions 1 and 2)
- ACIP Grading for LAIV in Children 2-8
- ACIP Grading for Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults
- GRADE: Inclusion of MenACWY-TT (MenQuadfi) as an option for meningococcal serogroup A, C, W, and Y (MenACWY) vaccination according to currently recommended dosing and schedules
- ACIP Grading of Recommendations Assessment, Development and Evaluation (GRADE) for 2-dose Rabies Vaccination Schedule
- ACIP Grading of Recommendations Assessment, Development and Evaluation (GRADE): PreHevbrio for Adults
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Adults aged ≥65 years
- GRADE: 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged 19–64 years with underlying medical conditions or other risk factors
- GRADE: 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years
- GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged 19–64 years with underlying medical conditions or other risk factors
- GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged ≥65 years
- GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged <2 years
- GRADE: PCV15 use in children aged 2–18 years with certain underlying medical conditions that increase the risk of pneumococcal disease
- GRADE: Serogroup B Meningococcal (MenB) vaccines for persons at increased risk for serogroup B meningococcal disease
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal Disease
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Meningococcal Conjugate Vaccines in HIV-Infected Persons
- ACIP Grading for Pneumococcal Vaccines for Immunocompromised Children
- ACIP Grading for Pneumococcal Vaccines for Immunocompromised Adults
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer Maternal RSV Vaccine
- ACIP Grading for Infant Meningococcal Vaccines
- ACIP Grading for Third Dose of Mumps Virus-Containing Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 1
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 2
- GRADE: Use of Smallpox Vaccine in Laboratory and Health-Care Personnel at Risk for Occupational Exposure to Orthopoxviruses
- ACIP Grade for use of PCV13 among adults ≥65 years old
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged ≥65 years who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) use among adults aged 19–64 years with an immunocompromising condition, cerebrospinal fluid leak, or cochlear implant who previously received a 13-valent pneumococcal conjugate vaccine (PCV13)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged 2 through 18 years with underlying medical conditions
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer’s Pentavalent Meningococcal Vaccine (MenACWY-TT/MenB-FHbp)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Tick-Borne Encephalitis (TBE) Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna COVID-19 Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Lyophilized CVD 103-HgR Vaccine Among Children and Adolescents Aged 2–17 Years
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Lyophilized CVD 103-HgR Vaccine.
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna mRNA RSV Vaccine (mResvia) in older adults
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Higher-Dose and Adjuvanted Influenza Vaccines for Solid Organ Transplant Recipients
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2024-2025 Formulation)
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among Adults Aged ≥19 Years Who Currently Have a Recommendation to Receive a Pneumococcal Conjugate Vaccine
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among Adults Aged 50–64 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among Adults Aged 19–49 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Use Haemophilus influenzae Type b-Containing Vaccines among American Indian and Alaska Native Infants
-
Evidence to Recommendations Frameworks
- ACIP Evidence to Recommendations (EtR) for Use of Bivalent COVID-19 Vaccine Booster Doses under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of COVID-19 Vaccine Booster Doses
- ACIP Evidence to Recommendations for Use of an Additional COVID-19 Vaccine Dose in Immunocompromised People
- ACIP Evidence to Recommendations for Use of Janssen COVID-19 Vaccine under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 Months–5 Years and Pfizer-BioNTech COVID-19 Vaccine in Children Ages 6 Months–4 Years under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 – 11 years and Adolescents Ages 12 – 17 years under an Emergency Use Authorization
- ACIP Evidence to Recommendations (EtR) for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine, Adjuvanted in adults ages 18 years and older under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine Among Children Aged 5–11 Under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine Among Persons Aged 12–15 Under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Pfizer-BioNTech COVID-19 Vaccine
- ACIP Update to the Evidence to Recommendations for a 2nd COVID-19 Booster Dose in Adults Ages 50 Years and Older and Immunocompromised Individuals
- ACIP Evidence to Recommendations Framework for Dengvaxia
- EtR for Ebola Vaccine
- ACIP Evidence to Recommendations for Use of GSK Adjuvanted RSVPreF3 Vaccine (AREXVY) in Adults Ages 60 and Older
- EtR for Tdap Vaccines in Adolescents and Adults
- EtR for Use of Hepatitis A Vaccine Catch-up
- EtR for Use of Hepatitis A Vaccine for Persons With HIV
- ACIP Evidence to Recommendations for a Universal Hepatitis B (HepB) Vaccination Strategy in Adults
- ACIP Evidence to Recommendations Framework for Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years
- ACIP Evidence to Recommendations for Booster Dose of Rabies Vaccine After the 2-dose Pre-exposure Prophylaxis Schedule
- EtR for HPV Vaccination of Adults, Ages 27 through 45 years
- EtR for HPV Vaccination Harmonization across Genders
- ACIP Evidence to Recommendations (EtR) Framework: Safety of Influenza Vaccines for Persons with Egg Allergy
- Evidence to Recommendations (EtR) Framework: Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged ≥65 Years
- ACIP Framework for Japanese Encephalitis Vaccine
- ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Booster Every 10 Years (Policy Question 4)
- ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Booster Every 2 Years (Policy Question 3)
- ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Heterologous for Those Who Received ACAM2000 Primary Series (Policy Question 5)
- ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Primary Series for Healthcare Personnel (Policy Question 2)
- ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Primary Series for Research, Clinical Laboratory, and Response Team Personnel (Policy Question 1)
- EtR for MenACWY-TT (MenQuadfi) Meningococcal Vaccine
- ACIP Evidence to Recommendations for Rabies Pre-exposure prophylaxis with a 2-dose Schedule
- ACIP Evidence to Recommendations for use of PreHevbrio Hepatitis B (HepB) Vaccine in Adults
- Evidence to Recommendations for PCV20 use among adults 19-64 years old
- Evidence to Recommendations for PCV20 use among adults ≥65 years old
- Evidence to Recommendations for PCV15 use among adults 19-64 years old
- Evidence to Recommendations for PCV15 use among adults ≥65 years old
- Evidence to Recommendations (EtR) Framework: PCV15 use in children aged 2–18 years with certain underlying medical conditions that increase the risk of pneumococcal disease
- Evidence to Recommendations for Serogroup B Meningococcal Vaccine Booster Dose Recommendations in Persons at Increased Risk of Meningococcal Disease During an Outbreak
- Evidence to Recommendations for Serogroup B Meningococcal Vaccine Booster Dose Recommendations in Persons at Increased Risk of Meningococcal Disease Because of Complement Deficiency, Complement Inhibitor Use, Asplenia, or Routine Exposure to Isolates of Neisseria meningitidis as a Microbiologist
- Evidence to Recommendations (EtR) Framework: PCV15 use in children aged <2 years
- EtR for use of PRIORIX for Prevention of Measles, Mumps, and Rubella
- ACIP Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season
- ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 months of age at increased risk of severe disease entering their second RSV season
- EtR for PCV13 use among adults ≥65 years old
- ACIP Evidence to Recommendations for Use of Pfizer RSVpreF in Pregnant People
- ACIP Evidence to Recommendations for Use of Pfizer Bivalent RSVpreF Vaccine (ABRSYVO) in Older Adults
- ACIP Update to the Evidence to Recommendations for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
- EtR Framework for Adults Aged ≥65 Years Who Have Previously Received Both PCV13 and PPSV23
- EtR Framework for Adults Aged ≥19 Years Who Have Previously Received PCV13 Only
- EtR Framework for Adults Aged 19–64 Years With an Immunocompromising Condition, Cochlear Implant, or Cerebrospinal Fluid Leak Who Have Previously Received Both PCV13 and PPSV23
- EtR framework for PCV20 use in children aged <2 years
- EtR framework for PCV20 use in children aged 2–18 years with certain underlying conditions that increase the risk of pneumococcal disease
- ACIP Evidence to Recommendations (EtR) for Use of an Additional Dose of Updated (2023-2024 Formula) COVID-19 Vaccine in Older Adults
- ACIP Evidence to Recommendations for Use of Pfizer’s Pentavalent Meningococcal Vaccine (MenACWY-TT/MenB-FHbp)
- ACIP Evidence to Recommendations for Primary Polio Vaccination Among Adults Aged ≥18 Years
- ACIP Evidence to Recommendations for Booster Doses of Inactivated Poliovirus Vaccine (IPV) Among Adults Aged ≥18 Years
- ACIP Evidence to Recommendations Framework for Tick-Borne Encephalitis (TBE) Vaccination for Persons Who Travel Abroad
- ACIP Evidence to Recommendations Framework for Tick-Borne Encephalitis (TBE) Vaccination for Laboratory Workers
- ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine
- ACIP Evidence to Recommendations for Use of Lyophilized CVD 103-HgR Vaccine Among Children and Adolescents Aged 2─17 years
- ACIP Evidence to Recommendations (EtR) for Use of an Updated (Monovalent XBB Containing) COVID-19 Vaccine Under an Emergency Use Authorization
- ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
- ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
- ACIP Evidence to Recommendations (EtR) Framework: High-Dose and Adjuvanted Influenza Vaccines for Solid Organ Transplant Recipients
- ACIP Evidence to Recommendations (EtR) for Use of 2024-2025 COVID-19 Vaccines in Persons ≥6 Months of Age
- EtR Framework for Adults Aged ≥19 Years Who Currently Have a Recommendation to Receive a Pneumococcal Conjugate Vaccine
- EtR Framework for Adults Aged 50–64 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication
- EtR Framework for Adults Aged 19–49 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication
- ACIP Evidence to Recommendations Regarding Use of Haemophilus influenzae Type b-Containing Vaccines Among American Indian and Alaska Native Infants